

Fourth Quarter and Full Year 2021 Results

March 28, 2022 • NASDAQ: MBII














This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations and plans, and future financial performance, including assumptions underlying such statements, are forward-looking statements, and should not be relied upon as representing the Company's views as of any subsequent date. Such forward-looking statements are based on information available to the Company as of the date of this presentation and involve a number of risks and uncertainties, some beyond the Company's control, that could cause actual results to differ materially from those anticipated by these forward-looking statements, including expected benefits and synergies of acquisitions; the potential exercise of the Company's warrants; and consumer, regulatory and other factors affecting demand for the Company's products, any difficulty in marketing MBI's products in global markets, competition in the market for pest management products, lack of understanding of bio-based pest management products by customers and growers, adverse decisions by regulatory agencies and other relevant third parties and any difficulty in integrating the acquired Pro Farm businesses. Additional information that could lead to material changes in the Company's performance is contained in its filings with the SEC. The Company is under no obligation to, and expressly disclaims any responsibility to, update or alter forward-looking statements contained in this presentation, future events or otherwise.

Product and Program names -- including Regalia[®], Regalia[®] CG, Regalia[®] Maxx, Regalia[®] Rx, Stargus[®], Grandevo[®] WDG, Grandevo[®] CG, Venerate[®] XC, Venerate[®] CG, Majestene[®], Haven[®], Amplitude[®], Zelto[®], Jet-Ag[®], Jet-Oxide[®], Pacesetter[®], Zequanox[®], BioUnite[™], Bio With Bite[®] and TerraConnect[™] -- are trademarks or registered trademarks of Marrone Bio Innovations.

UBP[™]-110, LumiBio[™], LumiBio Valta[™], LumiBio Kelta[™], Foramin[®], Emergen[™], Illustria[™], and Pro Farm[®] are trademarks or registered trademarks of Pro Farm Technologies.








Diversification Product Launches Pipeline Advancements

Product Mix Manufacturing Efficiencies Target: Adjusted EBITDA Breakeven









■ Q4 ■ Full Year



FY 2021 Cash Flow and Ending Cash

- Cash used in operations improved to \$10M from \$16M
- Ending cash increased \$3.8M to \$19.6M ○ Includes cash from final tranche of warrant exercises Warrant overhang removed

FY 2021 Net Debt



Wet debt increased \$1.7M

 Increase offset by higher ending cash



- Merger creates a **global leader** in the agriculture biologicals market
- Combined revenues +\$300M growing at a +20% CAGR over the past 4 years
- Business will be **fully integrated** from product discovery to active ingredient manufacturing; from commercialization to distribution
- Portfolio covers **all major biological product categories**, application types, and crop types, with highly complementary geographic footprints
- Scale enables **differentiation** in the highly-fragmented, high-growth biologicals market
- Strong R&D engine and robust product pipeline to help drive long-term organic growth
- Significant near-term cost and revenue synergy opportunities



Fourth-Quarter and Full-Year 2021 Results

\$ millions	Q4 2021	Q4 2020	Percent Increase (Decrease)	FY 2021	FY 2020	Percent Increase (Decrease)
Revenues	\$10.8	\$7.7	40.2%	\$44.3	\$38.4	15.5%
Gross Profit	\$6.5	\$4.9	31.5%	\$27.2	\$22.9	19.1%
Gross Margin	59.7%	63.7%	-400 bps	61.5%	59.6%	+190 bps
Operating Expenses	\$12.1	\$9.0	34.2%	\$42.7	\$40.1	6.5%
Operating Expense Ratio	111.6%	116.6%	-500 bps	96.3%	104.4%	-820 bps
Net Income (Loss)	(\$5.3)	(\$4.2)	26.2%	(\$16.6)	(\$20.2)	(17.9%)
Adj. EBITDA (Non-GAAP) ¹	(\$4.0)	(\$2.2)	78.7%	(\$8.7)	(\$11.0)	(21.2%)
Cash Used in Operations	(\$3.4)	(\$7.4)	(53.9%)	(\$10.0)	(\$16.0)	(37.6%)

¹Adjusted EBITDA is a non-GAAP financial measure and is further described to its most directly comparable GAAP measure in "GAAP to Non-GAAP Reconciliation."



GAAP to non-GAAP Reconciliation

	YEAR ENDED			YEAR ENDED	
		DECEMBER 31,		DECEMBER 31,	
		2021		2020	
Net Loss (AS REPORTED)	\$	(16,554)	\$	(20,168)	
Taxes		45		29	
Interest expense		1,570		1,443	
Depreciation and amortization		3,531		3,558	
EBITDA	\$	(11,408)	\$	(15,138)	
Stock based compensation	-	3,351	·	3,595	
Loss on modification of warrants				72	
Loss on issuance of new warrants		_		1,391	
Change in fair value of contingent consideration		(639)		445	
Reduction in expenses related to PPP funds		_		(1,396)	
Adjusted EBITDA	\$	(8,696)	\$	(11,031)	

Adjusted EBITDA is a non-GAAP financial measure and is further described to its most directly comparable GAAP measure in "GAAP to Non-GAAP Reconciliation."